Biogen’s Lupus Drug Reduces Disease Activity, Further Deresking I&I Pipeline

William Blair hailed a positive readout in cutaneous lupus erythematosus as a turning point for Biogen, while RBC Capital analysts called the results “another derisking step” for the company’s immunology and inflammation pipeline.